CClinicalTrials.gg
Not yet recruitingNCT07083427Updated Jul 24, 2025

CAPA In-vitro Oocyte Maturation (CUHK Medical Centre Limited)

An interventional study of CAPA-IVM in Infertility, Female, sponsored by Chinese University of Hong Kong. Not yet recruiting at 1 site in Hong Kong. Open to female participants aged 18 Years to 50 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2025-07-24.

Sponsored by Chinese University of Hong Kong · Not applicable, Interventional, and Other

Phase
Not applicable
Study type
Interventional
Enrollment
50
Allocation
Not applicable
Ages
18 Years to 50 Years
Sex
Female
01

Study summary

In vitro oocyte maturation (IVM) is a mild-approach assisted reproductive technology (ART). Because of its simplicity, the more favorable financial implications (reduced cost) for patients, and the lower health risk profile of IVM compared to controlled ovarian stimulation (COS) in polycystic ovary syndrome (PCOS) patients, the use of IVM in selected patients may gain increasing interest. Besides its application in patients with polycystic ovaries, IVM technology may have a role in fertility preservation, where young girls and adult women are facing infertility due to gonadotoxic chemotherapeutic treatment.

02

Conditions studied

  • Infertility, Female

Browse trials for

03

In context

Infertility, Female

540 studies on the registry are indexed under Infertility, Female; 138 are open to participants now.

This study's planned enrollment of 50 is below the median of 100 across 371 interventional studies indexed under Infertility, Female.

Browse Infertility, Female studies →

Lead sponsor

Chinese University of Hong Kong is the lead sponsor of 1,419 studies on the registry; 487 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 50 Years
Sexes eligible
Female
Accepts healthy volunteers
Yes

Inclusion criteria

  • Patients aged from 18-50 years old
  • Patients seek fertility preservation services
  • Patients seek oocyte retrieval services

Exclusion criteria

Exclusion Criteria:

  • Patients unable to provide consent/assent (i.e. significant psychiatric problems/cognitive delay)
05

Study design

Phase
Not applicable
Primary purpose
Other
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    CAPA-IVM

    In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.

    Other: CAPA-IVM

Interventions

  • OtherCAPA-IVM

    In CAPA-IVM, the oocyte is treated and matured outside the woman's body, while in classical IVF, the patient is treated. As a consequence, patients undergoing CAPA-IVM are not confronted with the typical risks and burden of systemic ovarian stimulation.

06

What researchers measure

Primary outcomes

  1. Number of mature oocytes

    Number of mature oocytes after IVM

    Time frame: 1 week

07

Study locations

1 site
  • Prince of Wales Hospital
    Hong Kong, Hong Kong
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jul 24, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT07083427
Lead sponsor
Chinese University of Hong Kong
Responsible party
Chung Pui Wah Jacqueline (Associate Professor, Chinese University of Hong Kong) — Principal investigator
First posted
Jul 24, 2025
Start date
Aug 1, 2025 (estimated)
Primary completion
Jun 30, 2035 (estimated)
Completion
Jul 1, 2036 (estimated)
Last update
Jul 24, 2025

Study contacts

Pui Wah Jacqueline Chung, MBBS
Contact
jacquelinechung@cuhk.edu.hk
3505 2745

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is not yet recruiting, as verified in Jul 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion